Valneva (VALN) said Monday the Brazilian Health Regulatory Agency has granted marketing authorization for its single-dose vaccine, IXCHIQ, for individuals 18 years and above to prevent disease caused by the chikungunya virus.
The decision marks the world's first approval of a chikungunya vaccine in an endemic country, the company said.
The approval allows for starting of large-scale clinical trials of the vaccine in Brazil, including phase 4 studies that support approval by the US Food and Drug Administration and the European Commission to generate additional data, it said.
Shares of Valneva were up over 7% in recent trading.
Price: 6.74, Change: +0.45, Percent Change: +7.20
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。